Literature DB >> 22749475

Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.

Dawn A Delfín1, Kara E Zang, Kevin E Schill, Nikita T Patel, Paul M L Janssen, Subha V Raman, Jill A Rafael-Fortney.   

Abstract

Cardiomyopathy is a significant component in Duchenne muscular dystrophy. Although mdx mice are deficient in dystrophin, they only develop mild indicators of cardiomyopathy before 1year-of-age, making therapeutic investigations using this model lengthy. In contrast, mdx mice also lacking utrophin (utrn(-/-);mdx) show severely reduced cardiac contractile function and histological indicators of cardiomyopathy by 8-10weeks-of-age. Here we demonstrate that utrn(-/-);mdx mice show a similar pattern of cardiac damage to that in dystrophic patients. Matrix metalloproteinases required for ventricular remodeling during the evolution of heart failure are upregulated in utrn(-/-);mdx mice concurrent with the onset of cardiac pathology by 10weeks-of-age. Matrix metalloproteinase activity is further dysregulated due to reduced levels of endogenous tissue inhibitors and co-localizes with fibroblasts and collagen I-containing scars. utrn(-/-);mdx mice are therefore a very useful model for investigating potential cardiac therapies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749475      PMCID: PMC3484217          DOI: 10.1016/j.nmd.2012.05.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  49 in total

Review 1.  Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007.

Authors:  H K Graham; M Horn; A W Trafford
Journal:  Acta Physiol (Oxf)       Date:  2008-06-28       Impact factor: 6.311

Review 2.  ECM remodeling in hypertensive heart disease.

Authors:  Bradford C Berk; Keigi Fujiwara; Stephanie Lehoux
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 3.  Dystrophin: from non-ischemic cardiomyopathy to ischemic cardiomyopathy.

Authors:  Qiang Sun Zheng; Wan Gang Guo; Zi Fan Lu; Xiao Qin Shi; Fei Fei Su; Hua Li
Journal:  Med Hypotheses       Date:  2008-06-17       Impact factor: 1.538

4.  Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice.

Authors:  Cristiane Bani; Jussara Lagrota-Candido; Douglas Florindo Pinheiro; Paulo Emílio Correa Leite; Maria Cristina Salimena; Andrea Henriques-Pons; Thereza Quirico-Santos
Journal:  Muscle Nerve       Date:  2008-05       Impact factor: 3.217

5.  Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling.

Authors:  Marcin Bujak; Marcin Dobaczewski; Khaled Chatila; Leonardo H Mendoza; Na Li; Anilkumar Reddy; Nikolaos G Frangogiannis
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

6.  Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice.

Authors:  Caroline Cheung; David Marchant; Elizabeth K-Y Walker; Zongshu Luo; Jingchun Zhang; Bobby Yanagawa; Maziar Rahmani; Jennifer Cox; Christopher Overall; Robert M Senior; Honglin Luo; Bruce M McManus
Journal:  Circulation       Date:  2008-03-10       Impact factor: 29.690

7.  Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle.

Authors:  DeWayne Townsend; Soichiro Yasuda; Sheng Li; Jeffrey S Chamberlain; Joseph M Metzger
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

8.  Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins.

Authors:  Hideyuki Ishihara; Hisashi Kubota; Raija L P Lindberg; David Leppert; Sergio M Gloor; Mariella Errede; Daniela Virgintino; Adriano Fontana; Yasuhiro Yonekawa; Karl Frei
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

Review 9.  MMP inhibitors in cardiac diseases: an update.

Authors:  György Dormán; Katalin Kocsis-Szommer; Cesare Spadoni; Péter Ferdinandy
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2007-11

10.  Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).

Authors:  Kazuhiro Fukushima; Akinori Nakamura; Hideho Ueda; Katsutoshi Yuasa; Kunihiro Yoshida; Shin'ichi Takeda; Shu-ichi Ikeda
Journal:  BMC Musculoskelet Disord       Date:  2007-06-28       Impact factor: 2.362

View more
  13 in total

1.  Limitations of Knockout Mice and Other Tools in Assessment of the Involvement of Matrix Metalloproteinases in Wound Healing and the Means to Overcome Them.

Authors:  Trung T Nguyen; William R Wolter; Bowen Anderson; Valerie A Schroeder; Ming Gao; Major Gooyit; Mark A Suckow; Mayland Chang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-24

2.  Claudin-5 levels are reduced from multiple cell types in human failing hearts and are associated with mislocalization of ephrin-B1.

Authors:  Sarah A Swager; Dawn A Delfín; Neha Rastogi; Honglan Wang; Benjamin D Canan; Vadim V Fedorov; Peter J Mohler; Ahmet Kilic; Robert S D Higgins; Mark T Ziolo; Paul M L Janssen; Jill A Rafael-Fortney
Journal:  Cardiovasc Pathol       Date:  2014-11-07       Impact factor: 2.185

3.  Duchenne Muscular Dystrophy Mice and Men: Can Understanding a Genetic Cardiomyopathy Inform Treatment of Other Myocardial Diseases?

Authors:  Jill A Rafael-Fortney; Jessica A Chadwick; Subha V Raman
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

Review 4.  Small and large animal models in cardiac contraction research: advantages and disadvantages.

Authors:  Nima Milani-Nejad; Paul M L Janssen
Journal:  Pharmacol Ther       Date:  2013-10-15       Impact factor: 12.310

Review 5.  Wasting mechanisms in muscular dystrophy.

Authors:  Jonghyun Shin; Marjan M Tajrishi; Yuji Ogura; Ashok Kumar
Journal:  Int J Biochem Cell Biol       Date:  2013-05-11       Impact factor: 5.085

6.  Cyclooxygenase-2 expression in skeletal muscle of knockout mice suffering Duchenne muscular dystrophy.

Authors:  Flavia de Oliveira; De Oliveira Flavia; Hananiah Tardivo Quintana; Jeferson André Bortolin; Odair Alfredo Gomes; Edson Aparecido Liberti; Daniel Araki Ribeiro
Journal:  Histochem Cell Biol       Date:  2012-11-28       Impact factor: 4.304

7.  Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.

Authors:  Zachary M Howard; Lisa E Dorn; Jeovanna Lowe; Megan D Gertzen; Pierce Ciccone; Neha Rastogi; Guy L Odom; Federica Accornero; Jeffrey S Chamberlain; Jill A Rafael-Fortney
Journal:  JCI Insight       Date:  2021-04-08

Review 8.  Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy.

Authors:  Yuji Ogura; Marjan M Tajrishi; Shuichi Sato; Sajedah M Hindi; Ashok Kumar
Journal:  Front Cell Dev Biol       Date:  2014-04-01

9.  Dystrophin Deficiency Causes Progressive Depletion of Cardiovascular Progenitor Cells in the Heart.

Authors:  Sarka Jelinkova; Yvonne Sleiman; Petr Fojtík; Franck Aimond; Amanda Finan; Gerald Hugon; Valerie Scheuermann; Deborah Beckerová; Olivier Cazorla; Marie Vincenti; Pascal Amedro; Sylvain Richard; Josef Jaros; Petr Dvorak; Alain Lacampagne; Gilles Carnac; Vladimir Rotrekl; Albano C Meli
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

10.  Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice.

Authors:  Sajedah M Hindi; Jonghyun Shin; Yuji Ogura; Hong Li; Ashok Kumar
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.